Spiera R, Unizony SH, Bao M, et al. - This study was undertaken to investigate the efficacy of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) presenting with polymyalgia rheumatica (PMR) symptoms only, cranial symptoms only, or both PMR and cranial symptoms in the GiACTA trial. Researchers enrolled a total of 250 patients with GCA who received either TCZ weekly or every other week plus a 26-week prednisone taper or PBO plus a 26- or 52-week prednisone taper. The outcomes of this study revealed that TCZ improved clinical outcomes in patients who presented with PMR symptoms only, cranial symptoms only or both at baseline, implying that TCZ is effective in patients with GCA regardless of presenting clinical phenotype.